Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $11.9 million.

  • Allogene Therapeutics' Cash from Investing Activities rose 11570.56% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.9 million, marking a year-over-year increase of 3249.45%. This contributed to the annual value of $75.7 million for FY2024, which is 5364.78% down from last year.
  • Per Allogene Therapeutics' latest filing, its Cash from Investing Activities stood at $11.9 million for Q3 2025, which was up 11570.56% from $43.8 million recorded in Q2 2025.
  • Allogene Therapeutics' Cash from Investing Activities' 5-year high stood at $112.9 million during Q1 2023, with a 5-year trough of -$76.0 million in Q3 2024.
  • In the last 5 years, Allogene Therapeutics' Cash from Investing Activities had a median value of $24.9 million in 2022 and averaged $30.0 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 74501.9% in 2021, then plummeted by 23759.08% in 2023.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Cash from Investing Activities stood at $29.2 million in 2021, then surged by 69.56% to $49.6 million in 2022, then skyrocketed by 36.02% to $67.5 million in 2023, then dropped by 18.57% to $54.9 million in 2024, then plummeted by 78.27% to $11.9 million in 2025.
  • Its last three reported values are $11.9 million in Q3 2025, $43.8 million for Q2 2025, and $6.2 million during Q1 2025.